ClinicalTrials.gg
CompletedNCT00370565Updated Feb 13, 2007

Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy.

A Phase 3 interventional study of Inhaled Human Insulin in Diabetes Mellitus, Type 2, sponsored by Pfizer. Completed at 52 sites in 2 countries. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2007-02-13.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
345
Allocation
Randomized
Ages
35 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 — none open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 2.

Enrollment
15th of 49
345 · median 129
Started
1999
the only one that year
Phase 3
25 of 49
none open now
Registered
12th of 49
by date

Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, this one is the 15th largest by enrollment, is the only one that started in 1999, is one of 25 in phase 3, and was the 12th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 35 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 as a file.
02

Study summary

To assess the impact on glucose control by inhaled insulin alone or added to two oral anti-diabetic agents in patients with type 2 diabetes who are not well controlled on 2 oral anti-diabetic agents.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
35 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 Diabetes Mellitus as defined by American Diabetes Association (ADA) at least 1 year earlier.
  • Patients were required to have been treated with a stable oral agent regimen involving 2 antidiabetc medications: 1 insulin secretagogue (a sulfonylurea or replabinide) and 1 insulin sensitizer (a thiazolidinedione or metformin).

Exclusion criteria

Exclusion Criteria:

  • Asthma,
  • Smoking during the previous 6 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
345 participants

Interventions

06

What researchers measure

Primary outcomes

  1. The primary efficacy endpoint is the change from baseline HbA1c measured at 12 weeks after randomization.

  2. HbA1c is measured at Weeks -4, -1, 0, 6, and 12 of comparative treatment. The baseline value is the mean of the Week -1 and Week 0 values.

Secondary outcomes

  1. Secondary: Efficacy: change in fasting plasma glucose and meal glucose response (2-h postprandial increment in plasma glucose)Fasting plasma glucose measured at Weeks -4, -1, 0, and 12 (the Weeks -1 and 12 measurements will be part of the meal studies)

  2. Meal glucose response measured at Week -1 and at Week 12;

  3. These results for efficacy are measured in the lab using plasma samples collected during clinic visits,

  4. not the subject's home glucose monitoring results.

  5. Comparison of 24-hour home glucose profiles.

  6. Proportion of subjects with acceptable or good glycemic control (e.g., HbA1c < 8.0% or <7.0%) at the end of treatment, incidence and severity of hypoglycemic episodes, discontinuation rate, change in fasting lipid profile, and change in body weight.

  7. A patient satisfaction and preference questionnaire will be administered at screening, at baseline, during active therapy, and at the end of the study.

07

Study locations

52 sites
  • Pfizer Investigational Site
    Irvine, California 92618, United States
  • Pfizer Investigational Site
    Long Beach, California 90806, United States
  • Pfizer Investigational Site
    Los Angeles, California 90059, United States
  • Pfizer Investigational Site
    Los Angeles, California 90073, United States
  • Pfizer Investigational Site
    Newport Beach, California 92663, United States
  • Pfizer Investigational Site
    San Diego, California 92108, United States
  • Pfizer Investigational Site
    Tustin, California 92780, United States
  • Pfizer Investigational Site
    New Britain, Connecticut 06050, United States
  • Pfizer Investigational Site
    New Haven, Connecticut 06510, United States
  • Pfizer Investigational Site
    New Haven, Connecticut 06519, United States
  • Pfizer Investigational Site
    Washington, District of Columbia 20007, United States
  • Pfizer Investigational Site
    Clearwater, Florida 33761, United States
  • Pfizer Investigational Site
    Hollywood, Florida 33021, United States
  • Pfizer Investigational Site
    Miami, Florida 33136, United States
  • Pfizer Investigational Site
    Tampa, Florida 33607, United States
  • Pfizer Investigational Site
    Louisville, Kentucky 40202, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70121, United States
  • Pfizer Investigational Site
    Minneapolis, Minnesota 55416, United States
  • Pfizer Investigational Site
    Columbia, Missouri 65212, United States
  • Pfizer Investigational Site
    St. Louis, Missouri 63141, United States
  • Pfizer Investigational Site
    Omaha, Nebraska 68131, United States
  • Pfizer Investigational Site
    New York, New York 10016, United States
  • Pfizer Investigational Site
    New York, New York 10025, United States
  • Pfizer Investigational Site
    Rochester, New York 14642, United States
  • Pfizer Investigational Site
    Greenville, North Carolina 27858, United States
  • Pfizer Investigational Site
    Winston-salem, North Carolina 27157, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44195, United States
  • Pfizer Investigational Site
    Portland, Oregon 97201-3098, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Pfizer Investigational Site
    Austin, Texas 78758, United States
  • Pfizer Investigational Site
    Dallas, Texas 75230, United States
  • Pfizer Investigational Site
    Dallas, Texas 75235-8858, United States
  • Pfizer Investigational Site
    Dallas, Texas 75246, United States
  • Pfizer Investigational Site
    Irving, Texas 75061, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229, United States
  • Pfizer Investigational Site
    Burlington, Vermont 05401, United States
  • Pfizer Investigational Site
    Renton, Washington 98055, United States
  • Pfizer Investigational Site
    Calgary, Alberta T3B 0M3, Canada
  • Pfizer Investigational Site
    Edmonton, Alberta T5H 3V9, Canada
  • Pfizer Investigational Site
    Edmonton, Alberta T6G 2C8, Canada
  • Pfizer Investigational Site
    Edmonton, Alberta T6G 2S2, Canada
  • Pfizer Investigational Site
    Red Deer, Alberta T4N 6V7, Canada
  • Pfizer Investigational Site
    Winnipeg, Manitoba R3A 1R9, Canada
  • Pfizer Investigational Site
    Winnipeg, Manitoba R3E 3P4, Canada
  • Pfizer Investigational Site
    St John's, Newfoundland and Labrador A1B 3V6, Canada
  • Pfizer Investigational Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Pfizer Investigational Site
    Ottawa, Ontario K1Y 4E9, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M5B 1WB, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M5C 2T2, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M5G 1X5, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M5G 2C4, Canada
  • Pfizer Investigational Site
    Laval, Quebec H7T 2P5, Canada
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 1999 and a completion of Sep 2000. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2006
First posted
Aug 31, 2006
Start
Jun 1999
Completion
Sep 2000
Last update
Feb 13, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Feb 13, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00370565
Lead sponsor
Pfizer
First posted
Aug 31, 2006
Start date
Jun 1999
Completion
Sep 2000
Last update
Feb 13, 2007

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion